Actinium Pharmaceuticals, Inc. (ATNM)

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Negative EBIT growth while AXSM is at 23.84%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.

Negative operating income growth while AXSM is at 35.57%. Joel Greenblatt would press for urgent turnaround measures.

Negative net income growth while AXSM stands at 19.26%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.

Negative EPS growth while AXSM is at 20.49%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.

Negative diluted EPS growth while AXSM is at 20.49%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.

Share count expansion well above AXSM's 1.17%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.

Diluted share count expanding well above AXSM's 1.17%. Michael Burry would fear significant dilution to existing owners' stakes.

No Data available this quarter, please select a different quarter.

Negative OCF growth while AXSM is at 25.25%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.

FCF growth under 50% of AXSM's 25.25%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.

Negative 3Y OCF/share CAGR while AXSM stands at 23.58%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.

Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.

Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.

Negative 3Y CAGR while AXSM is 11.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.

Negative equity/share CAGR over 10 years while AXSM stands at 360.64%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.

Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.

Below 50% of AXSM's 280.02%. Michael Burry suspects a serious short-term disadvantage in building book value.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Negative asset growth while AXSM invests at 7.23%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.

Under 50% of AXSM's 35.76%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.

Debt growth far above AXSM's 2.81%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.

R&D growth drastically higher vs. AXSM's 10.62%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.

SG&A growth well above AXSM's 7.86%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.